-PDUFA action date set for August 19, 2019- DUBLIN, Ireland , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that
DUBLIN, Ireland , Jan. 15, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, today announced that the Company will webcast its Analyst
-PDUFA action date now set for April 30, 2019- DUBLIN, Ireland , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced
-PDUFA action date set for June 30, 2019- DUBLIN, Ireland , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that
-Financing Strengthens Cash Position Ahead of Two Potential Product Launches in 2019- DUBLIN, Ireland , Dec. 21, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to
DUBLIN, Ireland , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced the submission of two New Drug Applications
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
- New Drug Application for CONTEPO ™ submitted to FDA in October 2018 - - Company preparing for potential commercialization of two, first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - DUBLIN, Ireland , Nov.
DUBLIN, Ireland , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced it has submitted a New Drug Application (NDA)
New data continue to support lefamulin and CONTEPO as potential first-in-class antibiotics in the United States that target the most common causative pathogens of CABP and cUTI, including multi-drug resistant (MDR) strains DUBLIN, Ireland , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics
